Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent
Abstract Wilson disease is an autosomal recessive genetic disorder caused by loss-of-function mutations in the P-type copper ATPase, ATP7B, which leads to toxic accumulation of copper mainly in the liver and brain. Wilson disease is treatable, primarily by copper-chelation therapy, which promotes co...
Main Authors: | Julia Smirnova, Ekaterina Kabin, Ivar Järving, Olga Bragina, Vello Tõugu, Thomas Plitz, Peep Palumaa |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2018-01-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-018-19873-2 |
Similar Items
-
Copper(II) partially protects three histidine residues and the N‐terminus of amyloid‐β peptide from diethyl pyrocarbonate (DEPC) modification
by: Merlin Friedemann, et al.
Published: (2020-06-01) -
Direct Competition of ATCUN Peptides with Human Serum Albumin for Copper(II) Ions Determined by LC-ICP MS
by: Andra Noormägi, et al.
Published: (2023-09-01) -
Metabolism of copper and possibilities for its regulation
by: Peep Palumaa
Published: (2023-11-01) -
In vitro fibrillization of Alzheimer’s amyloid-β peptide (1-42)
by: Ann Tiiman, et al.
Published: (2015-09-01) -
Evaluation of Zn<sup>2+</sup>- and Cu<sup>2+</sup>-Binding Affinities of Native Cu,Zn-SOD1 and Its G93A Mutant by LC-ICP MS
by: Julia Smirnova, et al.
Published: (2022-05-01)